FDA plan highlights drug safety efforts

被引：0

|

作者：

不详

机构：

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 1999年 / 56卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：408 / 408

页数：1

相关论文

共 50 条

[31] FDA's role in drug safety.
Graham, D.
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2007, 165 (11) : S93 - S93
[32] FDA drug labeling for pregnancy and lactation drug safety monitoring systems
Greene, Michael F.
SEMINARS IN PERINATOLOGY, 2015, 39 (07) : 520 - 523
[33] Post-market drug safety evidence sources: an analysis of FDA drug safety communications
Ishiguro, Chieko
Hall, Marni
Neyarapally, George A.
Dal Pan, Gerald
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (10) : 1134 - 1136
[34] Highlights of US CDER drug safety activity in 2003
Reactions Weekly, 2004, 1005 (1) : 3 - 3
[35] Post-marketing drug safety sources: An evaluation of the FDA's drug safety communications
Aldayel, Atheer
Alghamdi, Maha
Almutairi, Abdulaali
Al-Harbi, Fawaz F.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 302 - 302
[36] FDA MAY CHANGE DRUG USES IN 5-YEAR PLAN
Cima, Greg
JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2018, 253 (11): : 1375 - 1375
[37] Industry applauds FDA plan for faster cancer-drug review
Benowitz, S
SCIENTIST, 1996, 10 (09): : 1 - &
[38] US FDA reports new steps in drug safety
Reactions Weekly, 2007, 1138 (1) : 3 - 3
[39] Bolstering the FDA's drug-safety authority
Schultz, William B.
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22): : 2217 - 2219
[40] FDA under pressure of address drug safety issues
Wechsler, J
BIOPHARM INTERNATIONAL, 2005, 18 (02) : 16 - 17

← 1 2 3 4 5 →